REFERENCES
- Baumann U, Stocklossa C, Greiner W, Graf von der Schu-lenburg JM, von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003; 2: 84–90.
- Schreyögg J, Hollmeyer H, Bluemel M, Staab D, Busse R. Hospitalisation costs of cystic fibrosis. Pharmacoeconomics 2006; 24: 999–1009.
- Krauth C, Jalilvand N, Welt T, Busse R. Cystic fibrosis: cost of illness and consideration for the economic evaluation of po-tential therapies. Pharmacoeconomics 2003; 21: 1001–24.
- Johnson JA, Connonly MA, Jacobs P, Montgomery M, Brown NE, Zuberbuler P. Cost of care for individuate with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. Pharmacotherapy 1999; 19: 1159–66.
- Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003; 361: 681–9.
- Döring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000; 16: 749–67.
- Pseudomonas aeruginosa infection in people with cystic fi-brosis. Suggestion for prevention and infection control. Report of the UK Cystic Fibrosis Trust Infection Control Group. Cystic Fi-brosis Trust, Bromley 2004
- Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004197.
- Ratien F. Treatment of early Pseudomonas aeruginosa in-fection in patients with cystic fibrosis. Curr Opin Pulm Med 2006; 12: 428–32.
- Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mo-gayzel PJ Jr, Willey-Courand DB, et al., and Cystic Fibrosis Foun-dation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007; 176: 957–69.
- Iles R, Legh-Smith J, Drummond M, Prevost A, Vowler S. Economic evaluation of Tobramycin nebuliser solution in cys-tic fibrosis. J Cyst Fibros 2003; 2: 120–8.
- Taccetti G, Campana S, Festini F, Mascherini M, Daring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26: 458–61.
- Prontuario farmaceutico nazionale 2006 [Italian Directory of Medicine] website. (Accessed March 14, 2008 at http: //www.asl. fr. it/farmaci/NuovoPrFarm. pdf )
- Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary func-tion in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330–5.
- Kerem E, Conway S, Elborn S, Heijerman H for the Consensus Committee. Standards of care for patients with cystic fi-brosis: A European consensus. J Cyst Fibros 2005; 4: 7–26.
- Huot L, Durieu I, Bourdy S, Ganne C, Bellon G, Colin C, Touzet S. Evolution of costs of care for cystic fibrosis patients after clinical guidelines implementation in a French network. J Cyst Fibros 2008; in press.
- Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of in-haled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23–30.
- Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2003;(3): CD001021.
- Thornton J, Elliott RA, Tully MP, Dodd M, Webb AK. Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: comparing hospital and home care. J Cyst Fibros 2005; 4: 239–247
- Daring G, Heriby N for the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004; 3: 67–91.
- van den Akker-van Marie ME, Dankert HM, Verkerk PH, Dankert-Roelse JE. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics 2006; 118: 896–905.